About these ads

Retraction Watch

Tracking retractions as a window into the scientific process

Archive for the ‘oncology retractions’ Category

Paper about widely touted but unapproved “cure” for cancer, autism retracted

with 11 comments

int j cancerA paper about a protein being used — unapproved by health agencies — to treat diseases including cancer and autism has been retracted.

Here’s the notice from the International Journal of Cancer about a 2007 paper purporting to show that the substance, GcMAF, is useful against breast cancer: Read the rest of this entry »

About these ads

“Lack of experience and understanding” forces duplication retractions of liver cancer paper

with one comment

dovelogoA group of researchers in China has lost their paper on liver cancer after the first author admitted to duplication, also known, inelegantly, as self-plagiarism.

The paper, “Glycyrrhetinic acid-modified chitosan nanoparticles enhanced the effect of 5-fluorouracil in murine liver cancer model via regulatory T-cells,” appeared in the July 2013 issue of the Journal of Drug Design, Development and Therapy, a Dove Press title.

According to the abstract: Read the rest of this entry »

PLOS ONE retracts breast cancer genetics paper after claim of misappropriated data

with 5 comments

plosonePLOS ONE has retracted a 2012 article by a group of breast cancer researchers after another scientist — a leading U.S. oncologist — objected that the data came from his lab.

The paper, “GREB1 Functions as a Growth Promoter and Is Modulated by IL6/STAT3 in Breast Cancer,” came from a team composed of researchers at the Morehouse School of Medicine, Xavier University of Louisiana and the University of Miami School of Medicine. It purported to find that: Read the rest of this entry »

Written by amarcus41

July 17, 2014 at 9:30 am

Misconduct prompts retraction of prostatectomy paper

with 2 comments

jsrcoverA group of urologists in China has lost their 2012 paper in the Journal of Surgical Research because one of the authors was evidently rather naughty.

The article, “Is the impact of the extent of lymphadenectomy in radical prostatectomy related to the disease risk? A single center prospective study,” purported to show that: Read the rest of this entry »

Wayward “contractor” prompts expression of concern for PLoS ONE paper on cancer cells

with 8 comments

logoThe editors of PLoS ONE have issued an Expression of Concern (which seems likely to become a retraction) for a 2014 paper by a group of researchers in China who claim to have been led astray by a contractor hired to “edit the language” of the report.

The article, “Arsenic Sulfide Promotes Apoptosis in Retinoid Acid Resistant Human Acute Promyelocytic Leukemic NB4-R1 Cells through Downregulation of SET Protein,” came from a group in the Department of Hematology at the First Affiliated Hospital at Xi’an Jiaotong University, and was led by Yuwang Tian, a pathologist at the General Hospital of Beijing Military Area of PLA.

Or at least that’s what the manuscript eventually said. According to the expression of concern, however, that’s not what it said initially: Read the rest of this entry »

Cancer researcher facing criminal inquiry up to six retractions

with 32 comments

jbc 620Alfredo Fusco, who is under criminal investigation in Italy for scientific fraud, has had two more papers retracted.

Both are in the Journal of Biological Chemistry (JBC). Here are the two studies: Read the rest of this entry »

Cancer genetics group retracts three papers for “inappropriate presentation of data”

with 11 comments

jbc 620A group of cancer genetics researchers in Italy and the U.S. has retracted three papers in the Journal of Biological Chemistry (JBC) after it became aware they had duplicated some bands in their figures.

Here are the three papers: Read the rest of this entry »

Duplication forces retraction of liver cancer paper

with 4 comments

biomed research intBioMed Research International has retracted a 2013 paper after it became clear that it was lifted from another 2013 paper about the same subject by some of the same authors.

According to the retraction notice: Read the rest of this entry »

Written by amarcus41

June 18, 2014 at 11:30 am

Pfizer retracts another experimental cancer drug study

with 6 comments

clin cancer researchPfizer has retracted another study involving an experimental cancer drug that later failed later-stage trials.

The study, published in Clinical Cancer Research in 2010, looked at which patients might respond to the drug, called figitumumab. Here’s the notice: Read the rest of this entry »

Written by Ivan Oransky

June 13, 2014 at 1:00 pm

Authors plagiarize CME cancer article, lose their review paper

with 3 comments

or_miniOncology Reviews has retracted a 2014 paper on breast cancer after learning that the authors lifted parts of it from a continuing medical education lesson on Medscape.

The paper, “Challenges of combined everolimus/endocrine therapy in hormone receptor-positive metastatic breast cancer,” was written by Yousif Abubakr, of Thomas Jefferson University in Philadelphia, and Yasar Albushra, of King Faisal Specialist Hospital & Research Centre, in Saudi Arabia.

According to the retraction notice: Read the rest of this entry »

Written by amarcus41

June 12, 2014 at 11:30 am

Follow

Get every new post delivered to your Inbox.

Join 33,769 other followers